Notes for Contributors 2011 [Adobe PDF doc 528 kb]
Author's Transparency Financial Disclosure Form (2011) [MS Word doc 168 kb]
Copyright Form (2011) [MS Word doc 49 kb]
FT Publication Support Form (2011) [MS Word doc 96 kb]
RT Publication Support Form (2011) [MS Word doc 95 kb]
Mission Statement
The mission of Current Medical Research & Opinion (CMRO) is to provide ethical, unbiased and rapid publication of quality international content that is validated by rigorous peer review.
The journal's aim is to serve the information needs of the clinical medicine/research community and of the public and to help facilitate improvements in patient health by engendering a transparent, collaborative and honest approach to publication.
CMRO Aims & Scope
Current Medical Research & Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance.
See Aims & Scope for a fuller description of Aims and Scope and Types of Articles.
Rapid publication
Publication in CMRO is driven entirely by editorial considerations and independent authoritative peer review. We offer two prioritized modes of publication and a third non-prioritized mode. Regardless of the mode, the corresponding author of each article is given a total of 15 tokens for downloading full text of the article published online.
FastTrack:
This offers the most highly prioritized service, with a submission to online ('just accepted') publication timeline of 4-6 weeks (subject to 1-2 week author revision following initial peer review and prompt turnaround of proofs). There is a publication support fee for this expedited service, based on a charge of $850/€625/£550 per published page. In the event of author/sponsor-initiated withdrawal of the manuscript at any stage of the publication process and at the discretion of the Editorial Office, a partial page support fee will be charged. These charges support the expedient processing of material.
RapidTrack:
This prioritized service offers submission to online ('just accepted') publication in 8-10 weeks and is also subject to a publication support fee. In the event of author/sponsor-initiated withdrawal of the manuscript at any stage of the publication process and at the discretion of the Editorial Office, a partial page support fee will be charged. These charges support the expedient processing of material.
StandardTrack:
This non-prioritized service provides submission to online publication in 20 weeks and print publication up to 27 weeks; there are no publication support fees charged for this mode.
Pre-submission correspondence:
CMRO encourages contact with the Editorial Office preceding formal submission and particularly recommends prior contact for FastTrack and RapidTrack submissions where a particular publication deadline is desired. If you require further information, please contact:
Terri Metules, US Editor
E-Mail: tmetules@cmrojournal.com
Fizah Khan, UK Editor
E-Mail: fizah.khan@informa.com
Malavika Legge, Publisher
E-Mail: malavika.legge@informa.com
Peer Review
All manuscripts, whether prioritized or non-prioritized, undergo rigorous specialist peer review. The basic criterion for acceptance is that the work described must be clinically relevant and medically and scientifically accurate, demonstrating methodological rigor, clarity, balance and objectivity. The reviewing process is geared to provide authoritative help and constructive assistance in achieving the journal's aim to publish quality material rapidly.
Just Accepted
Your paper will be published as a Just Accepted article in 3 days (or 72 hours) of formal acceptance (providing the copyright form has been received). Just Accepted articles will appear as submitted by the authors and will not have undergone any copyediting, typesetting, or proofreading. A citation record will be sent to PubMed, which will be updated at the time your article is published online after copy editing and typesetting. Just Accepted format facilitates the quickest possible time from submission of your paper to publication of a citable article. If you are using a FastTrack or RapidTrack service you may opt out of the Just Accepted route. Please inform us as soon as possible if you choose to opt out.
Online and print publication
Articles in CMRO are published continuously online. The rapid publication of all accepted manuscripts is effected by posting on CMRO EarlyOnline. Articles published on the EarlyOnline site are:
- Full text, exactly as they will appear in the print issue
- Fully citable, with both final pagination and DOI information and made available as Epub ahead of print entries on PubMed
- Full text accessible from first appearance on EarlyOnline
Articles appear as e-Pub ahead of print papers (early online papers) within 2 weeks of the just accepted format for expedited papers and in 6 weeks of the just accepted format for non-expedited papers.
Articles appear in print issues 2-6 weeks after EarlyOnline publication, available in XML full text, PDF or PDF Plus (with CrossRef citation linking) formats.
Reprints
- Corresponding authors may order up to 100 author reprints at discounted rates at the proof production stage.
- Additional printed reprints for commercial use may be ordered at any time after preparation of proofs and can be made available 2 weeks from online publication (or 5 days on a rush basis). For all initial enquiries or commercial quotation requests for print and electronic reprints, click here
- Advice for a specific project may be sought ahead of submission and where possible should always be sought for any time-sensitive or priority material. Please send all initial enquiries to tmetules@cmrojournal.com
- A PDF of the article is made available to the corresponding author on EarlyOnline publication of the article for personal, academic use (but not for commercial distribution or hosting by institutional libraries).
- The corresponding author or other designated contact for all tracks (FastTrack, RapidTrack, and StandardTrack) are provided with 15 online access tokens, respectively, following EarlyOnline publication. These allow the download of a PDF, or the viewing of the online article, within each session.
Transparency Policy
CMRO supports and follows publishing practice guidelines and initiatives promulgated by such organizations as ICMJE, ISMPP, COPE, NLM and others that encourage transparency/disclosure of financial relationships with industry. CMRO is a member of COPE.
In an effort to provide transparency beyond those recommended by the aforementioned organizations, CMRO will ensure that any person in a position to influence the content of the journal provides a formal statement of relevant financial or other relationships with commercial entities which may lead to a real or perceived conflict of interest. These financial relationships shall be disclosed to CMRO's readers in print and/or on the CMRO website.
The Transparency Financial Discolsure policy form is available to download at the top of this page (click here go to the downloads section).
Plagiarism
CMRO has a strict policy against plagiarism, defined as the use of extracts from another person's work that are not placed in quotation marks, without the permission of that person and without acknowledgment to that person (using the appropriate reference style), with the result that the article presents these extracts as original to you. By submitting your work to an Informa journal, you warrant that it is your original work, and that you have secured the necessary written permission from the appropriate copyright owner or authority for the re-production of any text, illustration or other material.
If any article submitted to CMRO is found to have breached any of these conditions, CMRO reserves the right to reject that article and any others submitted by the same authors. CMRO may also contact the authors' affiliated institutions to inform them of its findings.
How To Submit
Formal submissions:
Manuscripts and accompanying files should be prepared in accordance with these Notes for Contributors and submitted to the CMRO Manuscript Central site http://mc.manuscriptcentral.com/cmro. Please indicate your preferred level of prioritized service in the covering letter.
CMRO's commitment is to provide a responsive and service-based approach to the publication of high-quality clinical evidence. The process is supported by discussion and comment on draft material prior to submission, followed by critically constructive, authoritative and independent peer review of material considered of clinical interest for the readership of the journal.
Pre-submission and editorial correspondence:
CMRO encourages authors to contact the Editorial Office ahead of formal submission and especially recommends prior contact for prioritized submissions where a particular publication deadline is desired.
Service levels:
The preferred service level is at the discretion of those submitting the manuscript. All contributions will continue to be evaluated by the Editorial Office to decide if they can be considered for peer review by the journal. Manuscripts from all service levels will be comprehensively assessed for the quality and robustness of the data material.
| Prioritised Service timelines: | |||
| Prioritised Services* |
Non-Prioritised Service |
||
| FastTrack | RapidTrack | StandardTrack | |
| Submission to online publication | 4-6 Weeks | 8-10 Weeks | Up to 20 Weeks |
*Prioritised services will incur publication support charges and the indicative timelines are subject to 1-2 week author revision (following initial peer review) and prompt turnaround of proofs
Editorial Offices
Terri Metules, CMRO Managing Editor (US)
CMRO/Informa Healthcare
52 Vanderbilt Avenue, 7th Floor
New York, NY 10017, USA
E-Mail: tmetules@cmrojournal.com
Tel.: +1 212 520 2748 | Fax: +1 201 794 6040
Fizah Khan, CMRO Senior Editor (UK)
CMRO/Informa Healthcare
Telephone House, 69-77 Paul Street
London, EC2A 4LQ, England
E-Mail: fizah.khan@informa.com
Tel.: +44 (0) 20 701 77654
Malavika Legge, CMRO Series Publisher
CMRO/Informa Healthcare
Telephone House, 69-77 Paul Street
London, EC2A 4LQ, England
E-Mail: malavika.legge@informa.com
Tel: +44 (0) 20 7017 6744 | Mobile: +44 (0) 78 2572 4407
Submitting a manuscript
Manuscripts for publication should conform to the latest Aims and Scope of the journal, delineated above.
All manuscripts should be submitted to the CMRO Manuscript Central site http://mc.manuscriptcentral.com/cmro. All material should be prepared as detailed below and conform to the Uniform Requirements for Manuscripts Submitted to Bio-medical Journals, prepared by the International Committee of Medical Journal Editors (www.icmje.org). Authors sending incomplete submissions may be asked to rectify any omissions or serious failures to follow the journal style, and to resubmit the paper. Recommendations are provided on page 10.
full details on submitting a manuscript can be found on the Submit a Manuscript page
Accepted file formats:
- Wordprocessor files:
Any common wordprocessor package can be used, although MS Word is preferred. Illustrations, graphics and tables should be embedded at the end of the manuscript as part of the document file, but all graphics must also be sent as individual editable files. - Graphic files:
These should be submitted both in the format of the application used to create the graphics (e.g. Illustrator, CorelDraw), in EPS format derived from these applications, or where this export format is not available as high-resolution JPEG files. If a dedicated drawing program has not been used, MS Word, Excel or PowerPoint formats are acceptable, if in their native format. Tables should be embedded and in proper table (MS Word) format.
Correspondence
All manuscripts must be accompanied by a covering letter signed by the principal author(s). This should include the following information:
- The name and contact details (telephone, fax, postal and email addresses) of the corresponding author or editorial contact who will address the comments from reviewers on the authors’ behalf and approve final proofs.
- A statement that the contribution represents original work; that it has not been previously published or simultaneously submitted for publication elsewhere; and that it has been read and approved by all the authors
- A statement that all the conditions as previously stated by the ICMJE have been met.
- A statement about the body providing explicit ethical approval of the work reported
- A statement of financial or other relationships of a declarable nature (i.e. commercial associations which might lead to a conflict of interest), including disclosure of sources of support in the form of sponsorship, grants, materials (drugs or equipment), and editorial or manuscript support (see also Acknowledgments below)
- A declaration stating potential or the absence of conflict of interest, even if there is no third-party sponsorship or support
- The name and contact details of the person to be responsible for payment of the Submission and Publication Support fees.
Manuscripts are acknowledged by Manuscript Central immediately upon receipt and are given a unique manuscript number that should be quoted in all future correspondence.
Prior publication:
CMRO will only consider work that has not been previously published in full. Abstract, poster or oral presentations and clinical trial registration do not constitute prior publication, but should be mentioned in the covering letter and the details included as a footnote on the manuscript title page.
Trial registration:
CMRO does not require trial registration as a condition of publication, but if a study which is the subject of the manuscript has been registered (e.g. to comply with FDAAA regulations), this should be mentioned in the covering letter. Trial registration numbers should be included in the Abstract and full details provided in the Methods section (see below).
Manuscript preparation
An excellent source of information on this topic can be found in the MPIP Authors' Submission Toolkit at:
http://informahealthcare.com/doi/pdf/10.1185/03007995.2010.499344
- General
Manuscripts submitted to Manuscript Central should be in English (British or American spelling) and written for an international, general medicine readership; where national or regional issues are discussed, the interna-tional context should also be considered. When a licensed drug or device is being discussed outside its licensed indication, or where an investigational drug or device is being discussed, this must be made clear to the reader.
Manuscripts should conform to the Vancouver style of the ICMJE uniform requirements. They should be double-spaced with numbered pages; margins of at least 25 mm or 1 in should be left on all sides. Instead of indenting, use two hard carriage returns to signify the end of paragraphs. Keep the layout as simple as possible - it will be set to house style during the production process.
- Title page:
The first page should include the full title of the paper (maximum of 150 characters, avoiding mention of trade or drug brand names), and the name(s) and initials of all the authors and their institutional affiliation(s) (normally, not exceeding seven individual names). Indicate the type of article, for example, Original Article or Review. - Address for correspondence:
The name and title of the corresponding author and postal mailing address (for scientific correspondence and author reprint requests) should be given in full, including telephone number and email address. - Abstract:
The second page should contain a structured abstract of the paper (usually no more than 300 words, to avoid possible truncation by Medline) summarizing the main facts, findings and principal conclusions. Suggested headings: Objective (including the reason for the study); Research design and methods (including study population and setting, study blinding, comparators, dosage, treatment regimens and durations, efficacy and safety issues); Clinical trial registration (if applicable); Main outcome measures; Results (both efficacy results and adverse events should be given in sufficient detail); Conclusions (qualified by any key limitations). - Key words:
4-7 key words are required, preferably drawn from the Index Medicus Medical Subject Heading (MeSH) list or phrases for indexing. - A Short title:
of 60 characters or fewer should also be provided for use as a running footer. - Previous presentation:
Should any of the material contained in the paper have been previously presented at a meeting, the full name, location and inclusive dates of the meeting should also appear on the title page.
- Title page:
- Organization of content
Headings should be used (with clear differentiation of heading levels) to provide structure to the text. Those articles reporting clinical trials or investigations should include the following key sections: - Introduction:
This section should state the clinical relevance and background to the study, and its rationale and purpose. - Patients and methods:
This should contain details of the study population and setting; subject selection (inclusion/exclusion criteria); methods of randomization and blinding; and efficacy and safety measures. The study design and statistical methodology should be described, along with justification for the choice of analysis and sample size given; CONSORT guidelines (www.consort-statement.org) should be considered where appropriate. All materials should be identified precisely, with drugs referred to by their generic names (with proprietary names, if required, given in parentheses along with the company name, city and country of the manufacturer), and with dose and routes of administration. The ethical approval procedure followed and the name of the ethics committee should be stated. Trial registration details should also be provided, where applicable. Indicate how adverse events were determined (and by whom) and indicate if/how compliance was measured.
For all reviews, especially systematic ones, provide details of literature database search methods: data-bases searched (this should normally be Medline and at least one or two others), search terms, inclusive dates and the selection criteria used. Brief mention of those should be included in the Abstract as well. - Results:
Use should be made of tables and figures to help in the clear presentation of results data. The sample size of each data point should be shown, with p-values and confidence intervals quoted for significant findings. Any data not included in the analysis (including patients withdrawn from the study) should be detailed. Details of data on efficacy and adverse events should be provided in a balanced fashion. - Discussion:
This should include implications of the findings and their limitations, with reference to all other relevant studies and the possibilities these suggest for future research. - Conclusion:
This must summarize the main paper, with a concise statement of the clinical implications of the study results. Ensure that extrapolations are reasonable and that conclusions are justified by the data presented, and indicate if the study design can be generalized to a broader patient population. - Transparency:
This section should have three sub-sections:
Declaration of funding
Should mention the sponsors for the study and the role of the sponsors in the preparation of this article. Details of differing contributorships of authors may also be included, where relevant.
Declaration of financial/other relationships
Should mention all relationships (financial, employment, other significant/relevant relationships) for each author. If there are no relationships to be declared for any of the authors, this should be explicitly stated.
Acknowledgments
All non-author assistance should be included here (e.g., medical writer(s), statistician...) together with the source for funding of such assistance. Acknowledgments of other non-author contributorships, e.g. list of investigators and study centers. - References:
Full references to relevant material cited in the text should be provided (see Reference style below). They should be comprehensive, accurate and up-to-date. Use primary references wherever possible and avoid 'Data on File', 'Poster' or other unpublished references. If bibliographic software has been used to generate cited references in a draft manuscript, please ensure that all reference-field linking is removed in the final version submitted for publication. - Figures and tables:
List figure captions together on a separate page. Each table (with caption above) should be presented on a separate page. Tables should be followed by figures (labeled with figure and/or part number) as embedded graphics at the end of the manuscript document
(For more details on preparation of figures and tables, see the 'Tables and illustrations' section below) - Drug proprietary names
All medical substances should be referred to by their Recommended International Non-proprietary Name (rINN). Proprietary or individual company trade names should only be mentioned where essential for clarity or to avoid confusion, for example, between different formulations.
Where proprietary names need to be used, they should be mentioned sparingly, with the generic name first, followed by the proprietary name in parentheses, company name and city and country of manufacturer. At first mention of a trade name* in the Abstract and first section of the main text, an asterisk should be used with a corresponding footnote giving details for the proprietary name, for example:
* Elidia is a registered trade name of Pathsco Ltd, Townsville, UK.
No ™ or ® symbols should be used anywhere in the manuscript and proprietary names should not appear in the title. - Dosages and measurements
These can be given in the units in which they were made, but non-SI units should be accompanied by SI equivalents, e.g. LDL-C <70 mg/dL (1.8 mmol/L). - Spelling, abbreviations, symbols and units
The Publisher will ensure that consistent British (The Concise Oxford Dictionary) or American (Webster's) spelling is used. If you have a preference for one or the other spelling, please state this in your covering letter. Ab-breviations should be defined at first mention; symbols should not be used unless first explained in the text.
(Please refer to Units, Symbols and Abbreviations, Royal Society of Medicine, London or Scientific Style and Format: The CBE Manual, Cambridge University Press, New York.) Only underline or italicize words or letters which are ¬required to appear in italics. All variables (e.g. p: probability values) or symbols for physical quantities (e.g. V: volume) should appear in italic type, and symbols for units, mathematical operators and for chemi-cal elements in roman type (e.g. g: gram; L: litre; Ca2+: calcium ions). Gene symbols (e.g. lexA gene) should be underlined or appear in italic type; proteins (e.g. LexA protein) should appear in roman type. - Reference style
These should be supplied in the Vancouver system and numbered consecutively (as Arabic numerals) in the order in which they are first mentioned in the text. The reference list should appear in the same sequence as the numbers in the text. Citations in the text should be in superscript preceding the punctuation. Examples of preferred forms are as follows:- Text citations in the form: ... annual influenza vaccines are therefore recommended1,2,8-14.
- List references in the form:
Journals:
1. Weissman P, Goldstein BJ, Rosenstock J et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of met-formin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin 2004;21:2029-35
Books:
2. Gottman J. Time Series Analysis. Cambridge: CUP, 1981
Working party reports and similar:
3. Clinical Disputes Forum Working Party. Pre-action protocol for the resolution of clinical disputes. London: Clinical Disputes Forum, 1998
For pre-publication articles assigned DOI numbers:
4. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Subjective complaints precede Parkinson disease: the Rotterdam study. Arch Neurol 2006: published online 9 January 2006, doi:10.1001/archneur.63.3.noc50312
For internet articles and website information:
5. Suicidality in adults being treated with antidepressant medications. FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2005. Available at: www.fda.gov/cder/drug/advisory/SSRI200507.htm [Last accessed 3 January 2006] - For citations with four or fewer authors, cite all names; for citations with more than four authors, cite three author names followed 'et al.'.
-
Tables and illustrations
These should be provided with short descriptive legends, numbered consecutively, and with their relevant position in the text clearly indicated. Legends (and labelling for illustrations) should be based on the 'stand-alone concept', so that looking at the tables and figures conveys an immediate, clear message without needing to refer to the text.- Tables should have concise headings to all columns and be identified by Arabic numerals, e.g. Table 2. They should be supplied within the manuscript file in cellular form rather than in simple tabbed form.
- Figures should be supplied electronically in the native format of the program used to produce them, in EPS format derived from these applications or, failing that, as high-resolution graphic files (JPEG or TIFF preferred). Ensure that the versions embedded in the manuscript match the files supplied. In exceptional circumstances, physical artwork may be supplied in a suitable finished form for reproduction and in proportion to the single-column width (84 mm or 3 in) or double-column width (175 mm or 6 in). All lettering should be of professional quality and/or generated by high-resolution computer graphics, and large enough to withstand appropriate reduction for publication. Please supply figures in black only (unless colour is essential) to avoid complications in converting colours to greyscale.
- Colour figures will only be accepted if colour is deemed to be essential, at the discretion of the Editor-in-Chief and Publisher. Use of colour in the printed journal will entail a charge on a scale related to the additional costs of colour reproduction.
- Authors are themselves responsible for seeking permission to reproduce material from other published sources. Such permission (and any copyright line, if required) should be reflected in the Figure or Table legend, e.g. Reproduced from Smith et al.33, with permission.
- Copyright assignment
Articles are published on the understanding that their copyright is assigned to the Publisher once they are accepted. If any material used is subject to third-party copyright, copyright clearance is the sole responsibility of the authors and must be supplied in writing to the Publisher. Corresponding authors will be sent a copyright form to sign upon submission of their paper. - Proofs and publication
Proofs are provided to the corresponding author or designated editorial contact for checking via the journal's online production tracking system. If, because of exceptional delays, time is limited, the Publisher reserves the right to have second or later proofs checked by the in-house editorial staff. No major alterations to the text will be accepted at proof stage. Electronic publication on CMRO Online will constitute formal publication of the article, with all subsequent critical changes or error corrections being dealt with via publication of a formal Erratum or Corrigendum. - Reprints
A copy of the print issue in which the article appears is supplied to the corresponding author on publication of the issue. PDFs for use as electronic reprints are made available to authors for limited personal use only. Cor-responding authors can order 100 offprints of their article at a special discounted rate at the proof production stage - these are available upon print publication of the issue.
Additional reprints for non-author/commercial use may be ordered (subject to quotation). Reprints can be pro-vided within 2-3 weeks of EarlyOnline publication (5–7 business days on a rush basis at an additional 15% charge). Additional printed reprints for commercial use may be ordered at any time after preparation of proofs, and can be made available for despatch 2-3 weeks from online publication (or 5-7 business days on a rush basis at an additional 15% charge). Please send all initial enquiries or quotation requests for print and electronic reprints to the contact e-mail addresses above. - Web updates
Please check this website (www.cmrojournal.com) for changes and updates to the submission procedures.
Types of Articles
Original Article
Full-length reports of an original study or clinical investigation (including reports of meta-analyses); length should not normally exceed 16 printed pages or 10,800 words.
Brief Report
A short report describing a preliminary research report of a clinical study, or new insight into diagnosis, treat-ment or clinical management. The body of the manuscript should have the same elements as a full paper, but should be written in an abbreviated form and as concisely as possible (running to an extent of 4-6 printed pages, equivalent to 2700-4050 words; less graphics).
Research Letter
An ultra-brief description of an aspect of a clinical investigation, a particular condition or an unusual case re-port of significant clinical interest written very concisely with 3-4 identifiable sections and a maximum of 10 references. A short 50-60 word summary abstract is required. This submission should have a maximum extent of two printed pages, 1350 words.
Review
A comprehensive, scholarly evidence-based review of the literature relating to an important, major clinical area, accompanied by critical analysis and leading to reasonable conclusions; length should not normally exceed 16 printed pages or 11,200 words. It is essential that details of the literature search methodology are provided, i.e. the databases searched (normally Medline and at least one or two other databases), the search terms and in-clusive dates, and any selectivity criteria imposed. Brief Reviews focusing on a specific drug or providing critical, objective insight on a particular clinical application of a therapy may also be considered (typically no more than 6-8 printed pages or 4050-5400 words).
Commentary
A knowledge-based or consensus-type article (e.g. working group statement) expressing objective opinions, experiences or perspectives on an important clinical area; details of the literature search methodology and/or basis for consensus should be provided.
Brief Comments
Normally solicited or commissioned by the Editor-in-Chief or Editorial Office.
Editorial
A brief commentary relating to a previously published article or one published in the same issue, or, a brief opinion or perspective on a specific topic. Editorials are generally written by the Editors or Editorial Board members, or are solicited or commissioned by the Editor-in-Chief. Unsolicited editorials may occasionally be considered and published with prior notice to the Editorial Office.
Letters to the Editor
A brief correspondence item commenting on an article published recently in the journal. A response to the comments would normally be sought from the authors of the original article and published in the same issue, where possible.
Supplements/Special issues
These include both traditional free-standing and in-journal collections of reviews and themed articles. Typically, these are based on updated contributions to symposium proceedings, moderated roundtable discussions, working group statements or workshop meetings. Suggestions and enquiries from potential guest editors, meeting organisers and sponsors are welcomed and actively encouraged. All supplementary articles are subject to rigorous peer review and need to comply with CMRO's transparent disclosure and publication policy. Please send all initial enquiries or quotation requests for print and electronic reprints to the contact email addresses above or malavika.legge@informa.com.
Submission Checklist
CMRO aims to process all manuscripts through the editorial process as smoothly and quickly as possible, especially for FastTrack and RapidTrack services. However, manuscripts sometimes are delayed due to minor editorial or formatting problems.
Please use the checklist below to help prepare your submission or resubmission. It will help us to process your manuscript swiftly. If you have any queries, please contact us at info@cmrojournal.com
To submit your manuscript to Manuscript Central, you will need:
A title page file with the names of all authors and coauthors.
Main document file with structured abstract, keywords, main text and references, trial registration infor-mation
Any extra files such as supplemental items to be published online only
Cover letter which includes:
a) Name and contact details of corresponding author
b) A statement that the contribution represents original work; has not been previously published or simultaneously submitted for publication; that the manuscript has been read and approved by all authors; and that all the conditions as previously stated by the ICMJE have been met
c) A statement of financial or other relationships of a declarable nature
d) The name and contact details of the person to be approached for support of the publication
The manuscript type (Original article, Brief report, Research letter, Review, Brief review, Commentary) clearly stated
Four to seven keywords
A short title of 60 characters or less
Section headings follow CMRO style
Proprietary drug names changed to generic equivalents except on first mention
No ® or ™ symbols.
(They should be replaced with an asterisked footnote indicating manufacturer's name and location at point of first occurrence in the Abstract and Introduction.)
An Acknowledgment section including declarations of interest by the authors, including grants, fellowships, or any commercial assistance or financial sponsorship received or of any affiliation, organization or entity which is relevant to the work reported. Any contributions to the research, data analysis or assistance in manuscript preparation should also be acknowledged in this section. A statement should declare "no competing interests" if this is the case.
References following CMRO style
All figures and tables cited in the text
Tables in cellular format and embedded in the manuscript
All figures supplied as editable, separate files as well as embedded in the manuscript
All supplementary material
Recommendations
Research papers should be presented as follows:
Title:
Should be concise but informative, and cannot contain brand names.
Authors' names
Keywords:
4-7 keywords or phrases to assist indexers in cross-referencing.
Address for correspondence:
Name and full postal address; telephone, fax and e-mail details.
Structured abstract (no more than 350 words):
Should state the purpose of the study and summarize the main facts, findings and conclusions.
Suggested headings:
- Objective (including reason for the study and main aims);
- Methods (including study population and setting, study blinding, comparators, dosage, treatment duration, principal efficacy and safety findings);
- Results (including both efficacy results and adverse events);
- Conclusions (qualified by any key limitations)
Should not contain any references.
Abbreviations should be defined at first mention and then redefined at their first mention in the main paper.
Introduction:
- Should state the background, rationale and purpose of the study
- Should not include data or conclusions
Patients and methods:
Should contain details of the study population (sex, age, source; e.g. prospective, retrospective, cross-sectional, and any other relevant characteristics); subject selection (inclusion/exclusion criteria, numbers selected, participation rate); methods of randomization and blinding; efficacy and safety measures; and how treatment was allocated. Crossover studies should give details of run-in/wash-out procedures.
Statistical methods should be described in sufficient detail to allow a knowledgeable reader with access to the original data to verify the reported results; measurement techniques, choice of analysis and sample size should be justified, and software packages should be defined.
State ethics committee approval and whether the procedures were in accordance with the Declaration of Helsinki (version).
Results:
Should be clearly presented and summarized as tables/figures where appropriate. Observed values should be presented.
The sample size for each data point should be quoted; p-values and confidence intervals (if available) should be presented for significant findings.
Mean values should not be quoted without some measure of variability. Standard deviation (SD) should be used to show variability among individuals. Standard error (SE) should be used to show the precision of the sample mean. Use of ± should be avoided and means should be presented as, 10.4 (SD 1.7) or 3.6 (SE 0.9), for example.
Results should be rounded appropriately (dependent on the result or value being given; e.g. mean, percentage). Rounding should not be used before or during analysis.
Details of the most frequent adverse event (<10%) should be listed by preferred term.
Details of withdrawn patients and those not included in the analyses should be given such that all patients are accounted for. Reasons for withdrawal(s) and characteristics of non-responders should also be given.
Discussion:
Should include implications of the findings and their limitations, with reference to other relevant studies and possible future research.
Do not repeat details of data given elsewhere.
Conclusions
Acknowledgments
This must include any declaration of interest by the authors (see CMRO Author Disclosure form, including grants, fellowships, any commercial assistance or financial sponsorship received, or any affiliation, organisation or entity which is relevant to the work reported. Some or all of this information may be published at the discretion of the Editor. All contributions to the research, data analysis or assistance in manuscript preparation (such as that of a medical writer) should also be acknowledged in this section.
References:
Should be numbered consecutively in the order in which they are first mentioned in the text. The following format should be used:
- Journals: Iyengar BS, Dorr RT, Remers WA. Chemical basis for the biological activity of Imexon and related Cyanaziridines. J Med Chem 2004;47 218-23
- Books: Gottman J. Time Series Analysis. Cambridge: CUP, 1981
- Working party reports and similar: Clinical Disputes Forum Working Party. Pre-action protocol for the resolution of clinical disputes. London: Clinical Disputes Forum, 1998
- Pre-publication articles assigned DOI numbers: de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Subjective complaints precede Parkinson disease: the Rotterdam study. Arch Neurol 2006: published online 9 January 2006, doi:10.1001/archneur.63.3.noc50312
- Internet articles and website information: Suicidality in adults being treated with antidepressant medications. FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2005. Available at: www.fda.gov/cder/drug/advisory/SSRI200507.htm [Last accessed 3 January 2006]
Spelling and Punctuation
Use open punctuation, e.g. UK not U.K., WHO not W.H.O.
Use Oxford or Webster dictionary spellings
Tables and Figures
All graphics must be cited in the text
Figures should be numbered consecutively according to the order in which they have been first cited in the text
If a figure has been published elsewhere, the original source must be acknowledged; written permission for reproduction from the copyright holder must be obtained and submitted
Simple line graphs and bar charts may be redrawn; we may request details of data point values
On bar charts please use open bars, black or striped shading, rather than tinted shading
When providing figures as electronic files, those created in Illustrator or Corel Draw are preferred. Electronic images should be saved as 300dpi bitmap images at the size of actual reproduction, no larger than 130 x 200mm
Figures are printed in black and white unless otherwise requested
Individual footnotes referring to trade names should be labelled in this hierarchy: *, †, ‡, $, ¶
